Detail Information of Post-Translational Modifications

General Information of Drug Transporter (DT)
DT ID	DTD0449 Transporter Info
Gene Name	SLC6A17
Transporter Name	Sodium-dependent neurotransmitter transporter
Gene ID	388662
UniProt ID	Q9H1V8

Post-Translational Modification of This DT
Overview ofSLC6A17 Modification Sites with Functional and Structural Information
Sequence	M P K N S K V T Q R E H S S E H V T E S V A D L L A L E E P V D Y K Q S V L N V A G E A G G K Q K A V E E E L D A E D R P A W N S K L Q Y I L A Q I G F S V G L G N I W R F P Y L C Q K N G G G A Y L V P Y L V L L I I I G I P L F F L E L A V G Q R I R R G S I G V W H Y I C P R L G G I G F S S C I V C L F V G L Y Y N V I I G W S I F Y F F K S F Q Y P L P W S E C P V V R N G S V A V V E A E C E K S S A T T Y F W Y R E A L D I S D S I S E S G G L N W K M T L C L L V A W S I V G M A V V K G I Q S S G K V M Y F S S L F P Y V V L A C F L V R G L L L R G A V D G I L H M F T P K L D K M L D P Q V W R E A A T Q V F F A L G L G F G G V I A F S S Y N K Q D N N C H F D A A L V S F I N F F T S V L A T L V V F A V L G F K A N I M N E K C V V E N A E K I L G Y L N T N V L S R D L I P P H V N F S H L T T K D Y M E M Y N V I M T V K E D Q F S A L G L D P C L L E D E L D K S V Q G T G L A F I A F T E A M T H F P A S P F W S V M F F L M L I N L G L G S M I G T M A G I T T P I I D T F K V P K E M F T V G C C V F A F L V G L L F V Q R S G N Y F V T M F D D Y S A T L P L T L I V I L E N I A V A W I Y G T K K F M Q E L T E M L G F R P Y R F Y F Y M W K F V S P L C M A V L T T A S I I Q L G V T P P G Y S A W I K E E A A E R Y L Y F P N W A M A L L I T L I V V A T L P I P V V F V L R H F H L L S D G S N T L S V S Y K K G R M M K D I S N L E E N D E T R F I L S K V P S E A P S P M P T H R S Y L G P G S T S P L E T S G N P N G R Y G S G Y L L A S T P E S E L
PTM type	X-N-glycosylation X-Oxidation X-Phosphorylation X-Ubiquitination X: Amino Acid

N-glycosylation
Asparagine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC6A17			[1]
Role of PTM	Potential impacts
Modified Residue	Asparagine	Modified Location	186
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-linked Glycosylation at SLC6A17 Asparagine 186 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC6A17			[1]
Role of PTM	Potential impacts
Modified Residue	Asparagine	Modified Location	393
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-linked Glycosylation at SLC6A17 Asparagine 393 has the potential to affect its expression or activity.
Oxidation
Cystine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC6A17			[2]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	90
Experimental Method	Co-Immunoprecipitation
Detailed Description	Oxidation at SLC6A17 Cystine 90 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC6A17			[2]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	366
Experimental Method	Co-Immunoprecipitation
Detailed Description	Oxidation at SLC6A17 Cystine 366 has the potential to affect its expression or activity.
Phosphorylation
Serine	12 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC6A17			[3], [4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	13
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Serine 13 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC6A17			[3], [4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	14
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Serine 14 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC6A17			[5]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	257
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Serine 257 has the potential to affect its expression or activity.
PTM Phenomenon4	Have the potential to influence SLC6A17			[4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	384
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Serine 384 has the potential to affect its expression or activity.
PTM Phenomenon5	Have the potential to influence SLC6A17			[6]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	418
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Serine 418 has the potential to affect its expression or activity.
PTM Phenomenon6	Have the potential to influence SLC6A17			[7], [8]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	665
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Serine 665 has the potential to affect its expression or activity.
PTM Phenomenon7	Have the potential to influence SLC6A17			[9], [10]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	682
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Serine 682 has the potential to affect its expression or activity.
PTM Phenomenon8	Have the potential to influence SLC6A17			[10], [11]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	686
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Serine 686 has the potential to affect its expression or activity.
PTM Phenomenon9	Have the potential to influence SLC6A17			[12]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	693
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Serine 693 has the potential to affect its expression or activity.
PTM Phenomenon10	Have the potential to influence SLC6A17			[4], [12]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	699
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Serine 699 has the potential to affect its expression or activity.
PTM Phenomenon11	Have the potential to influence SLC6A17			[7], [13]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	701
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Serine 701 has the potential to affect its expression or activity.
PTM Phenomenon12	Have the potential to influence SLC6A17			[12]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	706
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Serine 706 has the potential to affect its expression or activity.
Threonine	5 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC6A17			[4]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	380
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Threonine 380 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC6A17			[6]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	411
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Threonine 411 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC6A17			[9], [10]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	690
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Threonine 690 has the potential to affect its expression or activity.
PTM Phenomenon4	Have the potential to influence SLC6A17			[11], [13]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	700
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Threonine 700 has the potential to affect its expression or activity.
PTM Phenomenon5	Have the potential to influence SLC6A17			[12]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	705
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Threonine 705 has the potential to affect its expression or activity.
Tyrosine	4 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC6A17			[14], [15]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	261
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Tyrosine 261 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC6A17			[4], [16]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	377
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Tyrosine 377 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC6A17			[6]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	406
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Tyrosine 406 has the potential to affect its expression or activity.
PTM Phenomenon4	Have the potential to influence SLC6A17			[12]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	694
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC6A17 Tyrosine 694 has the potential to affect its expression or activity.
Ubiquitination
Lysine	7 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC6A17			[17], [18]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	34
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC6A17 Lysine 34 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC6A17			[19], [20]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	47
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC6A17 Lysine 47 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC6A17			[14], [17]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	49
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC6A17 Lysine 49 has the potential to affect its expression or activity.
PTM Phenomenon4	Have the potential to influence SLC6A17			[17]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	656
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC6A17 Lysine 656 has the potential to affect its expression or activity.
PTM Phenomenon5	Have the potential to influence SLC6A17			[14], [17]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	657
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC6A17 Lysine 657 has the potential to affect its expression or activity.
PTM Phenomenon6	Have the potential to influence SLC6A17			[17], [20]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	662
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC6A17 Lysine 662 has the potential to affect its expression or activity.
PTM Phenomenon7	Have the potential to influence SLC6A17			[14], [17]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	679
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC6A17 Lysine 679 has the potential to affect its expression or activity.

References
1	dbPTM in 2022: an updated database for exploring regulatory networks and functional associations of protein post-translational modifications. Nucleic Acids Res. 2022 Jan 7;50(D1):D471-D479. (ID: S6A17_HUMAN)
2	A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during Aging. Cell. 2020 Mar 5;180(5):968-983.e24.
3	Capillary Zone Electrophoresis-Tandem Mass Spectrometry for Large-Scale Phosphoproteomics with the Production of over 11,000 Phosphopeptides from the Colon Carcinoma HCT116 Cell Line. Anal Chem. 2019 Feb 5;91(3):2201-2208.
4	Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation. Nat Immunol. 2013 Nov;14(11):1166-72.
5	Global phosphoproteomic analysis reveals ARMC10 as an AMPK substrate that regulates mitochondrial dynamics. Nat Commun. 2019 Jan 10;10(1):104.
6	An Augmented Multiple-Protease-Based Human Phosphopeptide Atlas. Cell Rep. 2015 Jun 23;11(11):1834-43.
7	Refined phosphopeptide enrichment by phosphate additive and the analysis of human brain phosphoproteome. Proteomics. 2015 Jan;15(2-3):500-7.
8	Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell. 2016 Aug 11;166(4):1041-1054.
9	Phosphoproteomics reveals ALK promote cell progress via RAS/ JNK pathway in neuroblastoma. Oncotarget. 2016 Nov 15;7(46):75968-75980.
10	CEP128 Localizes to the Subdistal Appendages of the Mother Centriole and Regulates TGF-beta/BMP Signaling at the Primary Cilium. Cell Rep. 2018 Mar 6;22(10):2584-2592.
11	Improved Method for Determining Absolute Phosphorylation Stoichiometry Using Bayesian Statistics and Isobaric Labeling. J Proteome Res. 2017 Nov 3;16(11):4217-4226.
12	Targeted analysis of tyrosine phosphorylation by immuno-affinity enrichment of tyrosine phosphorylated peptides prior to mass spectrometric analysis. Methods. 2012 Feb;56(2):268-74.
13	Quantitative phosphoproteomics of Alzheimer's disease reveals cross-talk between kinases and small heat shock proteins. Proteomics. 2015 Jan;15(2-3):508-519.
14	Systematic functional prioritization of protein posttranslational modifications. Cell. 2012 Jul 20;150(2):413-25.
15	Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007 Dec 14;131(6):1190-203.
16	Phosphoproteome resource for systems biology research. Methods Mol Biol. 2011;694:307-22.
17	Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature. 2013 Apr 18;496(7445):372-6.
18	UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol. 2018 Jul;25(7):631-640.
19	Quantitative Analysis of the Brain Ubiquitylome in Alzheimer's Disease. Proteomics. 2018 Oct;18(20):e1800108.
20	Integrative Analysis of Proteome and Ubiquitylome Reveals Unique Features of Lysosomal and Endocytic Pathways in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells. Proteomics. 2018 Aug;18(15):e1700388.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Post-Translational Modifications

Visitor Map

Correspondence